Myriad Genetics (MYGN) has risen sharply, recording gains of 0.68% in the past 4 weeks. However, the stock has corrected -3.1% in the past 1 week, providing a good buying opportunity on dips. Myriad Genetics (MYGN) : During the past 4 weeks, traders have been relatively bearish on Myriad Genetics (MYGN), hence the stock is down -2.59% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.03% relative to the S&P 500.
The stock has recorded a 20-day Moving Average of 1.92% and the 50-Day Moving Average is 3.59%. Myriad Genetics, Inc. has dropped 13.94% during the last 3-month period . Year-to-Date the stock performance stands at -28.22%.
Myriad Genetics (NASDAQ:MYGN): On Fridays trading session , Opening price of the stock was $30.79 with an intraday high of $31.57. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $29.09. However, the stock managed to close at $30.98, a loss of 3.40% for the day. On the previous day, the stock had closed at $32.07. The total traded volume of the day was 1,738,183 shares.
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing, or assess a patients risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.